Literature DB >> 31821455

Resolution of secondary hemophagocytic lymphohistiocytosis after treatment with the JAK1/2 inhibitor ruxolitinib.

Scott R Goldsmith1,2, Sana Saif Ur Rehman2, Cara L Shirai3, Kiran Vij1,3, John F DiPersio1.   

Abstract

Entities:  

Year:  2019        PMID： 31821455      PMCID： PMC6963250          DOI： 10.1182/bloodadvances.2019000898

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  25 in total

1.  Salvage therapy with dose-escalating ruxolitinib as a bridge to allogeneic stem cell transplantation for refractory hemophagocytic lymphohistiocytosis.

Authors:  Yanmin Zhao; Jimin Shi; Xiaoqing Li; Jiasheng Wang; Jie Sun; Jianfeng Zhou; He Huang
Journal:  Bone Marrow Transplant       Date:  2019-06-04       Impact factor: 5.483

2.  IFNγR signaling mediates alloreactive T-cell trafficking and GVHD.

Authors:  Jaebok Choi; Edward D Ziga; Julie Ritchey; Lynne Collins; Julie L Prior; Matthew L Cooper; David Piwnica-Worms; John F DiPersio
Journal:  Blood       Date:  2012-09-12       Impact factor: 22.113

Review 3.  How I treat hemophagocytic lymphohistiocytosis in the adult patient.

Authors:  Alison M Schram; Nancy Berliner
Journal:  Blood       Date:  2015-03-10       Impact factor: 22.113

4.  Ruxolitinib as first-line treatment in secondary hemophagocytic lymphohistiocytosis: A single patient experience.

Authors:  Jessica Slostad; Patrick Hoversten; Candace L Haddox; Kamila Cisak; Jonas Paludo; Ayalew Tefferi
Journal:  Am J Hematol       Date:  2017-12-04       Impact factor: 10.047

5.  Recommendations for the management of hemophagocytic lymphohistiocytosis in adults.

Authors:  Paul La Rosée; AnnaCarin Horne; Melissa Hines; Tatiana von Bahr Greenwood; Rafal Machowicz; Nancy Berliner; Sebastian Birndt; Juana Gil-Herrera; Michael Girschikofsky; Michael B Jordan; Ashish Kumar; Jan A M van Laar; Gunnar Lachmann; Kim E Nichols; Athimalaipet V Ramanan; Yini Wang; Zhao Wang; Gritta Janka; Jan-Inge Henter
Journal:  Blood       Date:  2019-04-16       Impact factor: 22.113

6.  Treatment of hemophagocytic lymphohistiocytosis with HLH-94 immunochemotherapy and bone marrow transplantation.

Authors:  Jan-Inge Henter; AnnaCarin Samuelsson-Horne; Maurizio Aricò; R Maarten Egeler; Göran Elinder; Alexandra H Filipovich; Helmut Gadner; Shinsaku Imashuku; Diane Komp; Stephan Ladisch; David Webb; Gritta Janka
Journal:  Blood       Date:  2002-10-01       Impact factor: 22.113

7.  Ruxolitinib in corticosteroid-refractory graft-versus-host disease after allogeneic stem cell transplantation: a multicenter survey.

Authors:  R Zeiser; A Burchert; C Lengerke; M Verbeek; K Maas-Bauer; S K Metzelder; S Spoerl; M Ditschkowski; M Ecsedi; K Sockel; F Ayuk; S Ajib; F S de Fontbrune; I-K Na; L Penter; U Holtick; D Wolf; E Schuler; E Meyer; P Apostolova; H Bertz; R Marks; M Lübbert; R Wäsch; C Scheid; F Stölzel; R Ordemann; G Bug; G Kobbe; R Negrin; M Brune; A Spyridonidis; A Schmitt-Gräff; W van der Velden; G Huls; S Mielke; G U Grigoleit; J Kuball; R Flynn; G Ihorst; J Du; B R Blazar; R Arnold; N Kröger; J Passweg; J Halter; G Socié; D Beelen; C Peschel; A Neubauer; J Finke; J Duyster; N von Bubnoff
Journal:  Leukemia       Date:  2015-07-31       Impact factor: 11.528

8.  Performances of the H-Score for Diagnosis of Hemophagocytic Lymphohistiocytosis in Adult and Pediatric Patients.

Authors:  France Debaugnies; Bhavna Mahadeb; Alina Ferster; Nathalie Meuleman; Laurence Rozen; Anne Demulder; Francis Corazza
Journal:  Am J Clin Pathol       Date:  2016-06-12       Impact factor: 2.493

9.  Therapeutic effect of JAK1/2 blockade on the manifestations of hemophagocytic lymphohistiocytosis in mice.

Authors:  Sophia Maschalidi; Fernando E Sepulveda; Alexandrine Garrigue; Alain Fischer; Geneviève de Saint Basile
Journal:  Blood       Date:  2016-05-24       Impact factor: 22.113

10.  Janus kinase inhibition lessens inflammation and ameliorates disease in murine models of hemophagocytic lymphohistiocytosis.

Authors:  Rupali Das; Peng Guan; Leslee Sprague; Katherine Verbist; Paige Tedrick; Qi Angel An; Cheng Cheng; Makoto Kurachi; Ross Levine; E John Wherry; Scott W Canna; Edward M Behrens; Kim E Nichols
Journal:  Blood       Date:  2016-01-29       Impact factor: 22.113
View more
  10 in total

Review 1.  Haemophagocytic lymphohistiocytosis in pregnancy.

Authors:  Harold Wilson-Morkeh; Charlotte Frise; Taryn Youngstein
Journal:  Obstet Med       Date:  2021-09-26

Review 2.  JAK inhibition as a new treatment strategy for patients with COVID-19.

Authors:  Jin Huang; Chi Zhou; Jinniu Deng; Jianfeng Zhou
Journal:  Biochem Pharmacol       Date:  2022-07-03       Impact factor: 6.100

Review 3.  Treatment algorithm for COVID-19: a multidisciplinary point of view.

Authors:  Felice Galluccio; Tolga Ergonenc; Alvaro Garcia Martos; Abdallah El-Sayed Allam; Maria Pérez-Herrero; Ricardo Aguilar; Giacomo Emmi; Michele Spinicci; Ignacio Terrancle Juan; Mario Fajardo-Pérez
Journal:  Clin Rheumatol       Date:  2020-05-29       Impact factor: 2.980

4.  Ruxolitinib in conjunction with the HLH-94 protocol for Epstein-Barr virus-related hemophagocytic lymphohistiocytosis in the intensive care unit: A case report.

Authors:  Zoufang Huang; Jiangbo Xie
Journal:  Medicine (Baltimore)       Date:  2021-03-19       Impact factor: 1.817

5.  Ruxolitinib treatment permits lower cumulative glucocorticoid dosing in children with secondary hemophagocytic lymphohistiocytosis.

Authors:  Ying Chi; Rong Liu; Zhi-Xuan Zhou; Xiao-Dong Shi; Yu-Chuan Ding; Jian-Guo Li
Journal:  Pediatr Rheumatol Online J       Date:  2021-04-01       Impact factor: 3.054

Review 6.  Use of the JAK Inhibitor Ruxolitinib in the Treatment of Hemophagocytic Lymphohistiocytosis.

Authors:  Camille Keenan; Kim E Nichols; Sabrin Albeituni
Journal:  Front Immunol       Date:  2021-02-16       Impact factor: 7.561

Review 7.  COVID-19 as a mediator of interferon deficiency and hyperinflammation: Rationale for the use of JAK1/2 inhibitors in combination with interferon.

Authors:  H C Hasselbalch; V Skov; L Kjær; C Ellervik; A Poulsen; T D Poulsen; C H Nielsen
Journal:  Cytokine Growth Factor Rev       Date:  2021-04-14       Impact factor: 7.638

8.  Ruxolitinib in addition to standard of care for the treatment of patients admitted to hospital with COVID-19 (RUXCOVID): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  MeiLan K Han; Martti Antila; Joachim H Ficker; Ivan Gordeev; Alfredo Guerreros; Amparo Lopez Bernus; Antoine Roquilly; José Sifuentes-Osornio; Fehmi Tabak; Ricardo Teijeiro; Lorraine Bandelli; Diane S Bonagura; Xu Shu; James M Felser; Barbara Knorr; Weihua Cao; Peter Langmuir; Thomas Lehmann; Michael Levine; Sinisa Savic
Journal:  Lancet Rheumatol       Date:  2022-03-29

9.  Case report: Ruxolitinib as first-line therapy for secondary hemophagocytic lymphohistiocytosis in patients with AIDS.

Authors:  Xiang Liu; Xueling Zhu; Xiaotang Zhou; Yirui Xie; Dairong Xiang; Zhikai Wan; Ying Huang; Biao Zhu
Journal:  Front Immunol       Date:  2022-10-03       Impact factor: 8.786

Review 10.  Multifocal Pyoderma Gangrenosum with an Underlying Hemophagocytic Lymphohistiocytosis: Case Report and the Review of the Literature.

Authors:  Aleksandra Opalińska; Dominika Kwiatkowska; Adrian Burdacki; Mirosław Markiewicz; Dominik Samotij; Marek Dudziński; Jadwiga Niemiec-Dudek; Elżbieta Ostańska; Adam Reich
Journal:  Dermatol Ther (Heidelb)       Date:  2021-06-27
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.